



# International Wound Infection Institute

International Wound Infection Institute (IWII) Wound Infection in Clinical Practice. Wounds International. 2022.

## FULL CITATION LIST

1. Bjarnsholt T, Kirketerp-Møller K, Jensen PO, Madsen KG, Phipps R, Kroghfelt K, et.al. Why chronic wounds will not heal: A novel hypothesis. *Wound Repair Regen*, 2008; 16(1): 2-10.
2. James GA, Swogger E, Wolcott R, Pulcini Ed, Secor P, Sestrich J, Costerton JW, and Stewart PS. Biofilms in chronic wounds. *Wound Repair Regen*, 2008; 16(1): 37-44.
3. Kirketerp-Møller K, Jensen PO, Fazli M, Madsen KG, Pedersen J, and Moser C. Distribution, organization, and ecology of bacteria in chronic wounds. *J Clin Microbiol* 2008; 46(8): 2712-22.
4. Metcalf DG, Bowler PG, and Hurlow J. A clinical algorithm for wound biofilm identification. *J Wound Care*, 2014; 23(3): 137-42.
5. Jensen LK, Bjarnsholt T, Kragh KN, Aalbæk B, Henriksen NL, Blirup SA, Pankoke K, Petersen A, and Jensen HE. In vivo gentamicin susceptibility test for prevention of bacterial biofilms in bone tissue and on implants. *Antimicrob Agents Chemother*, 2019; 63(2).
6. Coenye T, Goeres D, Van Bambeke F, and Bjarnsholt T. Should standardized susceptibility testing for microbial biofilms be introduced in clinical practice? *Clin Microbiol Infect*, 2018; 24(6): 570-2.
7. Crabbé A, Jensen PØ, Bjarnsholt T, and Coenye T. Antimicrobial tolerance and metabolic adaptations in microbial biofilms. *Trends Microbiol*, 2019; 27(10): 850-63.
8. Cornforth DM, Dees JL, Ibberson CB, Huse HK, Mathiesen IH, Kirketerp-Møller K, Wolcott RD, Rumbaugh KP, Bjarnsholt T, and Whiteley M. *Pseudomonas aeruginosa* transcriptome during human infection. *Proc Natl Acad Sci U S A*, 2018; 115(22): E5125-e34.
9. World Union of Wound Healing Societies (WUWHS). 2008. Principles of best practice: Wound infection in clinical practice. An international consensus. MEP Ltd: London.
10. Kingsley A. A proactive approach to wound infection. *Nurs Stand*, 2001; 15(30): 50-8.
11. Siddiqui AR and Bernstein JM. Chronic wound infection: Facts and controversies. *Clin Dermatol*, 2010; 28(5): 519-26.
12. International Wound Infection Institute (IWII). 2016. Wound Infection in Clinical Practice. Wounds International.
13. Wolcott RD, Kennedy JP, and Dowd SE. Regular debridement is the main tool for maintaining a healthy wound bed in most chronic wounds. *J Wound Care*, 2009; 18(2): 54-6.
14. Wolcott RD, Rumbaugh KP, James G, Schultz G, Phillips P, Yang Q, Watters C, Stewart PS, and Dowd SE. Biofilm maturity studies indicate sharp debridement opens a time- dependent therapeutic window. *J Wound Care*, 2010 19(8): 320-8.
15. Buch PJ, Chai Y, and Goluch ED. Bacterial chatter in chronic wound infections. *Wound Repair Regen*, 2021; 29(1): 106-16.
16. Vestby LK, Grønseth T, Simm R, and Nesse LL. Bacterial biofilm and its role in the pathogenesis of disease. *Antibiotics (Basel)*, 2020; 9(2).
17. Nichols E. Describing a wound from presentation to healing. *Wound Essentials*, 2015; 10(1): 56-61.
18. Haesler E and Ousey K. Evolution of the Wound Infection Continuum. *Int Wound J*, 2018; 9(4): 6-10.
19. Haesler E, Swanson T, Ousey K, and Carville K. Clinical indicators of wound infection and biofilm: Reaching international consensus. *J Wound Care*, 2019; 28(3): S4-S12.
20. Haesler E, Larson D, Ousey K, Swanson T, Carville K, Bjarnsholt T, and IWII Committee. Establishing consensus on wound infection definitions. *World Union of Wound Healing Societies 2022 Hybrid Congress*. 2022. Abu Dhabi, UAE.
21. Bowler P. Bacterial growth guideline: Reassessing its clinical relevance. *Ostomy Wound Manage*, 2003; 49(1): 52-3.
22. Bowler P, Duerden B, and Armstrong DG. Wound microbiology and associated approaches to wound management. *Clin Microbiol Rev*, 2001 14(2): 244-69.
23. Kalan LR and Brennan MB. The role of the microbiome in nonhealing diabetic wounds. *Ann N Y Acad Sci*, 2019; 1435(1): 79-92.
24. Kirketerp-Møller K, Stewart PS, and Bjarnsholt T. The zone model: A conceptual model for understanding the microenvironment of chronic wound infection. *Wound Repair Regen*, 2020; 28(5): 593-9.
25. Vyas KS and Wong LK. Detection of biofilm in wounds as an early indicator for risk for tissue infection and wound chronicity. *Ann Plast Surg*, 2016; 76(1): 127-31.
26. World Union of Wound Healing Societies. Consensus document. Surgical wound dehiscence improving prevention and outcomes. Wounds International 2018.

27. Stryja J, Sandy-Hodgetts K, Collier M, et. al. Surgical site infection: Preventing and managing surgical site infection across health care sectors. *J Wound Care*, 2020; 29:2(S1-S69).
28. Sandy-Hodgetts K, Ousey K, Conway BR, Djohan R, Nair H, Serena T, and Tariq G. International best practice for the early identification and prevention of surgical wound complications. *Wounds International*, 2020.
29. Ata A, Lee J, Bestle SL, Desemone J, and Stain S. Postoperative hyperglycemia and surgical site infection in general surgery patients. *Arch Surg*, 2010; 145(9): 858-64.
30. Lecube A, Pachón G, Petriz J, Hernández C, and Simó R. Phagocytic activity is impaired in type 2 diabetes mellitus and increases after metabolic improvement. *PLoS One*, 2011; 6(8): e23366.
31. Schultz GS, Sibbald RG, Falanga V, Ayello EA, Dowsett C, Harding K, Romanelli M, Stacey MC, Teot L, and Vanscheidt W. Wound bed preparation: A systematic approach to wound management. *Wound Repair Regen*, 2003; 11(Suppl 1): S1-28.
32. Sørensen LT. Wound healing and infection in surgery: The pathophysiological impact of smoking, smoking cessation, and nicotine replacement therapy: A systematic review. *Ann Surg*, 2012 255(6): 1069-79.
33. Stechmiller JK. Understanding the role of nutrition and wound healing. *Nutr Clin Pract*, 2010; 25(1).
34. Torpy JM, Burke A, and Glass RM. Wound Infections. *JAMA* 2005; 294(16): 2122.
35. Gottrup F, Melling A, and Hollander DA. An overview of surgical site infections: aetiology, incidence and risk factors. *World Wide Wounds*, 2005.
36. Gouina JP and Kiecolt-Glaser J. The impact of psychological stress on wound healing: Methods and mechanisms. *Immunol Allergy Clin North Am*, 2011 31(1): 81-93.
37. Korol E, Johnston K, Waser N, Sifakis F, Jafri HS, Lo M, and Kyaw MH. A systematic review of risk factors associated with surgical site infections among surgical patients. *PLoS One*, 2013.
38. Haubner F, Ohmann E, Pohl F, Strutz J, and Gassner H. Wound healing after radiation therapy: Review of the literature. *Radiat Oncol*, 2012; 7: 162.
39. Cheadle WG. Risk factors for surgical site infection. *Surg Infect (Larchmt)*, 2006; 7(Suppl 1): S7-11.
40. Curtiss B, Hlavin S, Brubaker A, Kovacs ER, and Adek K. Episodic binge ethanol exposure impairs murine macrophage infiltration and delays wound closure by promoting defects in early innate immune responses. *Alcohol Clin and Exper Res*, 2014; 38(5): 1347-55.
41. Reichman D and Greenberg JA. Reducing surgical site infections: A review. *Rev Obstet Gynecol*, 2009; 2(4): 212-21.
42. Sen CK. Wound healing essentials: Let there be oxygen. *Wound Repair Regen*, 2009; 17(1): 1-18.
43. Sibbald R, Orsted H, Schultz G, Coutts P, and Keast D. Preparing the wound bed 2003: Focus on infection and inflammation. *Ostomy Wound Manage*, 2003; 49(11): 24-51.
44. Swanson T, Keast DH, Cooper R, Black J, Angel DE, Schultz G, Carville K, Fletcher J, and for the IWII. Ten top tips: Identification of wound infection in a chronic wound. *Wounds Middle East*, 2015; 2(1): 20-5.
45. Lipsky BA, Senneville E, Abbas ZG, Aragon-Sanchez J, Diggle M, Embil JM, Kono S, Lavery LA, Malone M, van Asten SA, Urbancic-Rovan V, and Peters EJG. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). *Diabetes Metab Res Rev*, 2020; 36(S1): e3280.
46. Ward D and Holloway S. Validity and reliability of semi-quantitative wound swabs. *British Journal of Community Nursing*, 2019; 24(Sup12): S6-S11.
47. Friedman ND, Bull AL, Russo PL, Leder K, Reid C, Billah B, Marasco S, McBryde E, and Richards MJ. An alternative scoring system to predict risk for surgical site infection complicating coronary artery bypass graft surgery. *Infect Control Hosp Epidemiol*, 2007; 28(10): 1162-8.
48. Figuerola-Tejerina A, Bustamante E, Tamayo E, Mestres CA, and Bustamante-Munguira J. Ability to predict the development of surgical site infection in cardiac surgery using the Australian Clinical Risk Index versus the National Nosocomial Infections Surveillance-derived Risk Index. *Eur J Clin Microbiol Infect Dis*, 2017; 36(6): 1041-6.
49. Raja SG, Rochon M, and Jarman JWE. Brompton Harefield Infection Score (BHIS): development and validation of a stratification tool for predicting risk of surgical site infection after coronary artery bypass grafting. *Int J Surg*, 2015; 16(Pt A): 69-73.
50. Nooh E, Griesbach C, Rösch J, Weyand M, and Harig F. Development of a new sternal dehiscence prediction scale for decision making in sternal closure techniques after cardiac surgery. *Journal of Cardiothoracic Surgery*, 2021; 16(1): 174.
51. Culver DH, Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG, Banerjee SN, Edwards JR, Tolson JS, Henderson TS, et al. Surgical wound infection rates by wound class, operative procedure, and patient risk index. National Nosocomial Infections Surveillance System. *Am J Med*, 1991; 91(3b): 152s-7s.
52. Sandy-Hodgetts K, Carville K, Santamaria N, Parsons R, and Leslie GD. The Perth Surgical Wound Dehiscence Risk Assessment Tool (PSWDRAT): development and prospective validation in the clinical setting. *J Wound Care*, 2019; 28(6): 332-44.
53. Dissemond J, Assadian O, Gerber V, Kingsley A, Kramer A, Leaper DJ, Mosti G, Piatkowski de Grzymala A, Riepe G, Risse A, Romanelli M, Strohal R, Traber J, Vassel-Biergans A, Wild T, and Eberlein T. Classification of wounds at risk and their antimicrobial treatment with polyhexanide: a practice-oriented expert recommendation. *Skin Pharmacol Physiol*, 2011; 24(5): 245-55.
54. Jockenhöfer F, Gollnick H, Herberger K, Isbary G, Renner R, Stücker M, Valesky E, Wollina U, Weichenthal M, Karrer S, Stoffels-Weindorf M, and Dissemond J. W.A.R. scores in patients with chronic leg ulcers: Results of a multicentre study. *J Wound Care*, 2014; 23(1): 5-6, 8, 10-2.
55. Lubelski D, Feghali J, Ehresman J, Pennington Z, Schilling A, Huq S, Medikonda R, Theodore N, and Sciubba DM. Web-based calculator predicts surgical-site infection after thoracolumbar spine surgery *World Neurosurgery*, 2021; 151: e571-e8.
56. Siaw-Sakyi V. Early wound infection identification using the WIRE tool in community health care settings: An audit report. *British journal of community nursing*, 2017; 22(Supplement12): S20-S7.

57. Dumville JC, Gray TA, Walter CJ, Sharp CA, Page T, Macefield R, Blencowe N, Milne TK, Reeves BC, and Blazeby J. Dressings for the prevention of surgical site infection. *Cochrane Database Syst Rev*, 2016; 12(12): Cd003091.
58. Eberlein T. Critical colonisation and local infection - Current therapy by use of polihexanide. 2009.
59. Woods E, Davis P, Barnett J, and Percival SL, Wound healing, immunology and biofilms, in *Microbiology of Wounds*, Percival SL and Cutting K, Editors. 2010, CRC Press.
60. Edmiston CE, McBain AJ, Kiernan M, and Leaper DJ. A narrative review of microbial biofilm in postoperative surgical site infections: Clinical presentation and treatment. *J Wound Care*, 2016; 25(12): 693-702.
61. Lindsay S, Oates A, and Bourdillon K. The detrimental impact of extracellular bacterial proteases on wound healing. *Int Wound J*, 2017; 14(6): 1237-47.
62. Newton H, Edwards J, Mitchell L, and Percival SL. Role of slough and biofilm in delaying healing in chronic wounds. *Br J Nurs*, 2017; 26(Sup20a): S4-s11.
63. Percival SL. Importance of biofilm formation in surgical infection. *Br J Surg*, 2017; 104(2): e85-e94.
64. Ellis S, Lin EJ, and Tartar D. Immunology of wound healing. *Curr Derm Rep*, 2018; 7: 350–8.
65. Krzyszczyk P, Schloss R, Palmer A, and Berthiaume F. The role of macrophages in acute and chronic wound healing and interventions to promote pro-wound healing phenotypes. *Front Physiol*, 2018; 9(419).
66. Withycombe C, Purdy KJ, and Maddocks SE. Micro-management: curbing chronic wound infection. *Mol Oral Microbiol*, 2017; 32(4): 263-74.
67. Weir D and Schultz G, Assessment and management of wound-related infections, in *Wound, Ostomy and Continence Nurses Society Core Curriculum: Wound Management*, Doughty D and McNichol L, Editors. 2016, Wolters-Kluwer: Philadelphia.
68. Ousey K, Roberts D, and Gefen A. Early identification of wound infection: Understanding wound odour. *J Wound Care*, 2017; 26(10): 577-82.
69. Sganga G, Pea F, Aloj D, Corcione S, Pierangeli M, Stefani S, Rossolini GM, and Menichetti F. Acute wound infections management: The 'don'ts' from a multidisciplinary expert panel. *Expert Review of Anti-Infective Therapy*, 2020; 18(3): 231-40.
70. Schultz G, Bjarnsholt T, James GA, Leaper DJ, McBain AJ, Malone M, Stoodley P, Swanson T, Tachi M, and Wolcott RD. Consensus guidelines for the identification and treatment of biofilms in chronic nonhealing wounds. *Wound Repair Regen*, 2017; 25(5): 744-57.
71. Rahim K, Saleha S, Zhu X, Huo L, Basit A, and Franco OL. Bacterial contribution in chronicity of wounds. *Microb Ecol*, 2017; 73(3): 710-21.
72. Leaper DJ, Schultz G, Carville K, Fletcher J, Swanson T, and Drake R. Extending the TIME concept: What have we learned in the past 10 years? *Int Wound J*, 2012; 9(Suppl 2): 1-19.
73. Edwards HE, Parker CN, Miller C, Gibb M, Kapp S, Ogrin R, Anderson J, Coleman K, Smith D, and Finlayson KJ. Predicting delayed healing: The diagnostic accuracy of a venous leg ulcer risk assessment tool. *Int Wound J*, 2018; 15(2): 258-65.
74. Siaw-Sakyi V. Early wound infection identification using the WIRE tool in community health care settings: An audit report. *Br J Community Nurs*, 2017; 22(Supplement12): S20-S7.
75. Guest JF, Fuller GW, and Vowden P. Venous leg ulcer management in clinical practice in the UK: Costs and outcomes. *Int Wound J*, 2018; 15(1): 29-37.
76. Guest JF, Fuller GW, and Vowden P. Diabetic foot ulcer management in clinical practice in the UK: Costs and outcomes. *Int Wound J*, 2018; 15(1): 43-52.
77. Oropallo AR, Andersen C, Abdo R, Hurlow J, Kelso M, Melin M, and Serena TE. Guidelines for point-of-care fluorescence imaging for detection of wound bacterial burden based on delphi consensus. *Diagnostics* 2021; 11: 1219.
78. Dowsett C, Bellingeri A, Carville K, Garten A, and Woo K. A route to more effective infection management: The Infection Management Pathway. *Wounds Int*, 2020; 11(3): 50-7.
79. Vestjens J, Rondas A, White R, and Holloway S. The inter-rater reliability between nurse-assessors clinically assessing infection of chronic wounds using the WUWHS criteria. *Int Wound J*, 2018; 15(1): 8-15.
80. Ennis WJ. Chronic Wound Assessment and Treatment System (CWATS), in *Wound and Lymphedema: Focus on Resource-limited Settings*, Keast D, Editor. 2020, World Alliance for Wound and Lymphedema Care: Denmark.
81. Serena TE, Harrell K, Serena L, and Yaakov RA. Real-time bacterial fluorescence imaging accurately identifies wounds with moderate-to-heavy bacterial burden. *J Wound Care*, 2019; 28(6): 346-57.
82. Gardner SE, Hillis SL, and Frantz RA. Clinical signs of infection in diabetic foot ulcers with high microbial load. *Biol Res Nurs*, 2009; 11(2): 119-28.
83. Gardner SE, Franz RA, and Doebbeling BN. The validity of the clinical signs and symptoms used to identify localized chronic wound infection. *Wound Repair Regen*, 2001; 9(3): 178-86.
84. Centers for Disease Control and Prevention. Healthcare-associated Infections: Surgical Site Infection (SSI). 2010.
85. Wilson AP, Treasure T, Sturridge MF, and Gruneberg RN. A scoring method (ASEPSIS) for postoperative wound infections for use in clinical trials of antibiotic prophylaxis. *Lancet* 1986; 1(8476): 311-13.
86. Wilson APR, Weavill C, Burrige J, and Kelsey MC. The use of the wound scoring method 'ASEPSIS' in postoperative wound surveillance. *J Hosp Infect*, 1990; 16(4): 297-309.
87. Wilson APR, Webster A, Gruneberg RN, Treasure T, and Sturridge MF. Repeatability of ASEPSIS wound scoring method. *Lancet*, 1986; 327(8491): 1208-9.
88. Fierheller M and Sibbald RG. A clinical investigation into the relationship between increased periwound skin temperature and local wound infection in patients with chronic leg ulcers. *Adv Skin Wound Care*, 2010; 23(8): 369-81.

89. Monteiro-Soares M, Russell D, Boyko EJ, Jeffcoate W, Mills JL, Morbach S, and Game F. Guidelines on the classification of diabetic foot ulcers (IWGDF 2019). *Diabetes Metab Res Rev*, 2020; 36 (S1) (e3273).
90. Bravo-Molina A, Linares-Palomino JP, Vera-Arroyo B, Salmerón-Febres LM, and Ros-Díe E. Inter-observer agreement of the Wagner, University of Texas and PEDIS classification systems for the diabetic foot syndrome. *Foot Ankle Surg*, 2018; 24(1): 60-4.
91. Oyibo SO, Jude EB, Tarawneh I, Nguyen HC, Harkless LB, and Boulton AJ. A comparison of two diabetic foot ulcer classification systems: The Wagner and the University of Texas wound classification systems. *Diabetes Care*, 2001; 24(1): 84-8.
92. Sibbald RG, Woo K, and Ayello EA. Increased bacterial burden and infection: The story of NERDS and STONES. *Adv Skin Wound Care*, 2006; 19(8): 447-61.
93. Woo KY and Sibbald RG. A cross-sectional validation study of using NERDS and STONEES to assess bacterial burden. *Ostomy Wound Manage*, 2009; 55(8): 40-8.
94. Dissemmond J, Gerber V, Lobmann R, Kramer A, Mastronicola D, Senneville E, Moisan C, Edwards-Jones V, Mahoney K, Junka A, Bartoszewicz M, Verdú-Soriano J, and Strohal R. Therapeutic index for local infections score (TILI): a new diagnostic tool. *J Wound Care*, 2020; 29(12): 720-6.
95. Dowsett C and von Hallern B. The Triangle of Wound Assessment: A holistic framework from wound assessment to management goals and treatments. *Wounds Int*, 2017; 8(4): 34-9.
96. Sanger PC, van Ramshorst GH, Mercan E, Huang S, Hartzler AL, Armstrong CA, Lordon RJ, Lober WB, and Evans HL. A prognostic model of surgical site infection using daily clinical wound assessment. *J Am Coll Surg*, 2016; 223(2): 259-70.e2.
97. EPUAP, NPIAP, and PPPIA. Prevention and Treatment of Pressure Ulcers/Injuries: Clinical Practice Guideline. 2019, Haesler E., editor. EPUAP/NPIAP/PPPIA.
98. Blanco-Blanco J, Gea-Sánchez M, Valenzuela-Pascual F, Barallat-Gimeno E, Espart A, and Escobar-Bravo M. Are the classic signs of infection in concordance with results from percutaneous aspiration to diagnose infection in pressure injuries? *J Adv Nurs*, 2017; 73(6): 1433-42.
99. Bui UT, Edwards HE, and Finlayson KJ. Identifying risk factors associated with infection in patients with chronic leg ulcers. *Int Wound J*, 2018; 15(2): 283-90.
100. LeBlanc K, Cambell K, Beeckman D, Dunk AM, Harley C, Hevia H, Holloway S, Idensohn P, Langemo D, Ousey K, Romanelli M, Vuagnat H, and Woo K. 2018. Best Practice Recommendations for the Prevention and Management of Skin Tears in Aged Skin. *Wounds International*.
101. Li S, Renick P, Nair A, and Tang L. Diagnostics for wound infections. *Adv Wound Care*, 2020; prepub.
102. Barrett CD, Celestin A, Fish E, Glass CC, Eskander MF, Murillo R, Gospodinov G, Gupta A, and Hauser CJ. Surgical wound assessment by sonography in the prediction of surgical wound infections. *J Trauma Acute Care Surg*, 2016; 80(2): 229-36.
103. Fleck C. Identifying infection in chronic wounds. *Advances in Skin and Wound Care*, 2006; 19(1): 20-1.
104. Kingsley AR. The wound infection continuum and its application to clinical practice. *Ostomy Wound Manage*, 2003; 47(suppl A): S1-S.
105. Copeland-Halperin LR, Kaminsky AJ, Bluefeld N, and Miraliakbari R. Sample procurement for cultures of infected wounds: a systematic review. *J Wound Care*, 2016; 25(4): S4-6, s8-10.
106. Healy B and Freedman A. ABC of wound healing: Infections. *BMJ* 2006; 332(7545): 838-41.
107. Edward-Jones G, Collection, transport, and laboratory processing of wound, tissue and bone samples, in *Essential microbiology for wound care*, Edward-Jones V, Editor. 2016, University press: Oxford. p. 33-51.
108. Kelly F. Infection control: Validity and reliability in wound swabbing. *Br J Nurs*, 2003; 12(16): 959-64.
109. Gardner SE, Frantz R, Hillis SL, Park H, and Scherubel M. Diagnostic validity of semiquantitative swab cultures. *Wounds*, 2007; 19(2): 31-8
110. Angel DE, Lloyd P, Carville K, and Santamaria N. The clinical efficacy of two semi-quantitative wound-swabbing techniques in identifying the causative organism(s) in infected cutaneous wounds. *Int Wound J*, 2011; 8(2): 176-85.
111. Huang Y, Cao Y, Zou M, Luo X, Jiang Y, Xue Y, and Gao F. A Comparison of Tissue versus Swab Culturing of Infected Diabetic Foot Wounds. *International Journal of Endocrinology*, 2016; 2016.
112. Davidson MW. *Microscopy U*. 2016. Available from: <http://www.microscopyu.com/>.
113. Wilson SM and Antony B. Preparation of plant cells for transmission electron microscopy to optimize immunogold labeling of carbohydrate and protein epitopes, Table 1: Advantages and limitations of different microscopy techniques. *Nat Protoc*, 2012; 7: 1716-27.
114. Achinas S, Yska SK, Charalampogiannis N, Krooneman J, and Euverink GJW. A technological understanding of biofilm detection techniques: A review. *Materials (Basel, Switzerland)*, 2020; 13(14): 3147.
115. Rhoads DD, Wolcott RD, Sun Y, and Dowd SE. Comparison of culture and molecular identification of bacteria in chronic wounds. *Int J Mol Sci*, 2012; 13(3): 2535-50.
116. Gardner SE, Hillis SL, Heilmann K, Segre JA, and Grice EA. The neuropathic diabetic foot ulcer microbiome is associated with clinical factors. *Diabetes Metab Res Rev*, 2013; 62(3): 923-30.
117. Dowd SE, Sun Y, Secor PR, Rhoads DD, Wolcott BM, James GA, and Wolcott RD. Survey of bacterial diversity in chronic wounds using pyrosequencing, DGGE, and full ribosome shotgun sequencing. *BMC Microbiol* 2008; 8: 43.
118. Kelley ST, Theisen U, L.T. A, St. Amand A, and Pace NR. Molecular analysis of shower curtain biofilm microbes. *Appl Environ Microbiol*, 2004; 70(7): 4187-92.
119. Attinger C and Wolcott R. Clinically addressing biofilm in chronic wounds. *Adv Wound Care* 2012 1(3): 127-32.
120. McGuire J and D'Alessandro J. Combating biofilms in the chronic wound. *Podiatry Today* 2016; 29(8).
121. Kalan L, Loesche M, Hodkinson BP, Heilmann K, Ruthel G, Gardner SE, and Grice EA. Redefining the chronic-wound microbiome: Fungal communities are prevalent, dynamic, and associated with delayed healing. *mBio*, 2016; 7(5).

122. Kalan LR, Meisel JS, Loesche MA, Horwinski J, Soaita I, Chen X, Uberoi A, Gardner SE, and Grice EA. Strain- and Species-Level Variation in the Microbiome of Diabetic Wounds Is Associated with Clinical Outcomes and Therapeutic Efficacy. *Cell Host Microbe*, 2019; 25(5): 641-55.e5.
123. Costerton JW, Cheng KJ, Geesey GG, Ladd TI, Nickel JC, Dasgupta M, and Marrie TJ. Bacterial biofilms in nature and disease. *Ann Rev Microbiol*, 1987; 41: 435-64.
124. Stodley P, Sauer K, Davies DG, and Costerton JW. Biofilms as complex differentiated communities. *Ann Rev Microbiol* 2002; 56(1): 187-209.
125. Davis SC, Ricotti C, Cazzaniga A, Welsh E, Eaglstein WH, and Mertz PM. Microscopic and physiologic evidence for biofilm-associated wound colonization in vivo. *Wound Repair Regen*, 2008; 16(1): 23-9.
126. Malone M, Bjarnsholt T, McBain AJ, James GA, Stoodley P, Leaper D, Tachi M, Schultz G, Swanson T, and Wolcott RD. The prevalence of biofilms in chronic wounds: A systematic review and meta-analysis of published data. *J Wound Care*, 2017; 26(1): 20-5.
127. Metcalf D and Bowler PG. Perceptions of wound biofilm by wound care clinicians. *Wounds*, 2019; 31(3): E14-E7.
128. Swanson T, Grothier L, and Schultz G. 2014. Wound Infection Made Easy. *Wounds International*.
129. Thaarup IC and Bjarnsholt T. Current in Vitro biofilm-infected chronic wound models for developing new treatment possibilities. *Adv Wound Care (New Rochelle)*, 2021; 10(2): 91-102.
130. Bjarnsholt T, Whiteley M, Rumbaugh KP, Stewart PS, Jensen P, and Frimodt-Møller N. The importance of understanding the infectious microenvironment. *Lancet Infect Dis*, 2021.
131. Bay L, Barnes CJ, Fritz BG, Thorsen J, Restrup MEM, Rasmussen L, Sørensen JK, Hesselvig AB, Odgaard A, Hansen AJ, and Bjarnsholt T. Universal dermal microbiome in human skin. *mBio*, 2020; 11(1).
132. Alhede M, Lorenz M, Fritz BG, Jensen P, Ring HC, Bay L, and Bjarnsholt T. Bacterial aggregate size determines phagocytosis efficiency of polymorphonuclear leukocytes. *Med Microbiol Immunol*, 2020; 209(6): 669-80.
133. Bay L, Kragh KN, Eickhardt SR, Poulsen SS, Gjerdrum LMR, Ghathian K, Calum H, Ågren MS, and Bjarnsholt T. Bacterial aggregates establish at the edges of acute epidermal wounds. *Adv Wound Care (New Rochelle)*, 2018; 7(4): 105-13.
134. Hurlow J and Bowler PG. Clinical experience with wound biofilm and management: A case series. *Ostomy Wound Manage*, 2009; 55(4): 38-49.
135. Metcalf D and Bowler P. Biofilm delays wound healing: A review of the evidence. *Burns & Trauma*, 2013; 1(1): 5-12.
136. Malone M and Swanson T. Biofilm-based wound care: The importance of debridement in biofilm treatment strategies. *Br J Community Nurs*, 2017; 22(Sup6): S20-s5.
137. Fazil M, Bjarnsholt T, Kirketerp-Møller K, Jørgensen B, Andersen AS, Krogfelt KA, Givskov M, and Tolker-Nielsen T. Non-random distribution of *Pseudomonas aeruginosa* and *Staphylococcus aureus* in chronic wounds. *J Clin Microbiol*, 2009; 47(12): 4084-9.
138. Malone M, Fritz BG, Vickery K, Schwarzer S, Sharma V, Biggs N, Radzieta M, Jeffries TT, Dickson HG, Jensen SO, and Bjarnsholt T. Analysis of proximal bone margins in diabetic foot osteomyelitis by conventional culture, DNA sequencing and microscopy. *Apmis*, 2019; 127(10): 660-70.
139. Bianchi T, Wolcott RD, Peghetti A, Leaper D, Cutting K, Polignano R, Rosa Rita Z, Moscatelli A, Greco A, Romanelli M, Pancani S, Bellingeri A, Ruggeri V, Postacchini L, Tedesco S, Manfredi L, Camerlingo M, Rowan S, Gabrielli A, and Pomponio G. Recommendations for the management of biofilm: A consensus document. *J Wound Care*, 2016; 25(6): 305-17.
140. Rhoads DD, Wolcott RD, and Percival S. Biofilms in wounds: Management strategies. *J Wound Care*, 2008 17(11): 502-8.
141. Wolcott R. Economic aspects of biofilm-based wound care in diabetic foot ulcers. *J Wound Care*, 2015; 24(5): 189-94.
142. Avsar P, Patton D, Ousey K, Blackburn J, O'Connor T, and Moore Z. The impact of surgical site infection on health-related quality of life: A systematic review. *Wound Manag Prev*, 2021; 67(6): 10-9.
143. Gompelman M, van Asten SAV, and Peters EJG. Update on the role of infection and biofilms in wound healing: pathophysiology and treatment. *Plast Reconstr Surg*, 2016; 138(3 Suppl): 61s-70s.
144. World Union of Wound Healing Societies (WUWHS). 2020. Optimising wound care through patient engagement. *Wounds International*.
145. Waters N. Using the WOUND mnemonic for whole patient assessment. *WCET Journal*, 2011; 31(1): 41-3.
146. International consensus. 2012. Optimising wellbeing in people living with a wound. An expert working group review. *Wounds International: London*.
147. Fletcher J and Barrett S. Improving holistic assessment of chronic wounds: How to meet patient expectation using the new best practice statement. *Wounds UK*, 2018; 14(5): 92-5.
148. Wounds UK. Best Practice Statement: Improving holistic assessment of chronic wounds. 2018. London: Wounds UK.
149. Rochon M, Magboo R, Barlow C, Ibrahim S, Carruthers L, Pagett J, Morais C, and Silva E. Implementing enhanced patient education for surgical site infection prevention in cardiac surgery. *Br J Nurs*, 2020; 29(17): 994-1002.
150. Moore Z, Dowsett C, Smith G, Atkin L, Bain M, Lahmann NA, Schultz GS, Swanson T, Vowden P, Weir D, Zmuda A, and Jaimes H. TIME CDST: An updated tool to address the current challenges in wound care. *J Wound Care*, 2019; 28(3): 154-61.
151. Gibson JAG, Yarrow J, Brown L, Evans J, Rogers SN, Spencer S, and Shokrollahi K. Identifying patient concerns during consultations in tertiary burns services: Development of the Adult Burns Patient Concerns Inventory. *BMJ Open*, 2019; 9(12): e032785.
152. Alvarez OM, Kalinski C, Nusbaum J, Hernandez L, Pappous E, Kyriannis C, Parker R, Chrzanowski G, and Comfort CP. Incorporating wound healing strategies to improve palliation (symptom management) in patients with chronic wounds. *J Palliat Med*, 2007; 10(5): 1161-89.
153. Moore Z, Butcher G, Corbett L, McGuinness W, Synder R, and van Acker K. Managing wounds as a team. *J Wound Care*, 2014; 23(5 Suppl): S1-38.
154. Atkin L and Tettelbach W. TIMERS: Expanding wound care beyond the focus of the wound. *Br J Nurs*, 2019; 28(20): S34-S7.

155. Sibbald RG, Elliott JA, Persaud-Jaimangal R, Goodman L, Armstrong DG, Harley C, Coelho S, Xi N, Evans R, Mayer DO, Zhao X, Heil J, Kotru B, Delmore B, LeBlanc K, Ayello EA, Smart H, Tariq G, Alavi A, and Somayaji R. Wound bed preparation 2021. *Adv Skin Wound Care*, 2021; 34(4): 183-95.
156. Burden M and Thornton M. Reducing the risks of surgical site infection: the importance of the multidisciplinary team. *Br J Nurs*, 2018; 27(17): 976-9.
157. Schultz GS, Barillo DJ, Mozingo DW, and Chin GA. Wound bed preparation and a brief history of TIME. *Int Wound J*, 2004; 1(1): 19-32.
158. Wolcott RD and Rhoads DD. A study of biofilm-based wound management in subjects with critical limb ischaemia. *J Wound Care*, 2008; 17(4): 145-55.
159. Weir D, Wound Dressings, in *Local Wound Care for Dermatologist*, Alavi A and Maibach H, Editors. 2020, Springer, Cham. p. 25-34.
160. Haesler E and Carville K. 2022. Australian Standards for Wound Prevention and Management. Australian Health Research Alliance, Wounds Australia and WA Health Translation Network.
161. Weir D and Swanson T. Ten top tips: Wound cleansing. *Wounds Int*, 2019; 10(4): 8-11.
162. Murphy C, Atkin L, Swanson T, Tachi M, Tan YK, de Ceniga MV, Weir D, Wolcott R, Ānohorská J, Ciprandi G, Dissemond J, James GA, Hurlow J, Lázaro Martínez JL, Mrozikiewicz-Rakowska B, and Wilson P. Defying hard-to-heal wounds with an early antibiofilm intervention strategy: wound hygiene. *J Wound Care*, 2020; 29(Sup3b): S1-s26.
163. Fernandez R, Griffiths R, and Ussia C. Effectiveness of solutions, techniques and pressure in wound cleansing. *JBI Reports*, 2004; 2(7): 231-70.
164. Kent D, Scardillo J, Dale B, and Pike C. Does the use of clean or sterile dressing technique affect the incidence of wound infection? *J Wound Ostomy Cont Nurs*, 2018; 45(3): 265-9.
165. McLain NE, Moore ZE, and Avsar P. Wound cleansing for treating venous leg ulcers. *Cochrane Database Syst Rev*, 2021; 3: Cd011675.
166. Milne J. The importance of skin cleansing in wound care. *Br J Nurs*, 2019; 28(12): S20-s2.
167. Ubbink DT, Brölmann FE, Go PMNYH, and Vermeulen H. Evidence-based care of acute wounds: A perspective. *Adv Wound Care*, 2015; 4(5): 286-94.
168. Percival SL, Mayer D, Malone M, Swanson T, Gibson D, and Schultz G. Surfactants and their role in wound cleansing and biofilm management. *J Wound Care*, 2017; 26(11): 680-90.
169. Edwards-Jones V, Flanagan M, and Wolcott R. Technological advancements in the fight against antimicrobial resistance. *Wounds Int*, 2015; 6(2): 47-51.
170. White W and Asimus M, Chapter 8: Assessment and Management of Non-viable Tissue, in *Wound Management for the Advanced Practitioner*, Swanson T, Asimus M, and McGuinness W, Editors. 2014, IP Communications.
171. Kramer A. Case for wound cleansing. *J Wound Care*, 2020; 29(Sup10a): S3-s4.
172. Kramer A, Dissemond J, Kim S, Willy C, Mayer D, Papke R, Tuchmann F, and Assadian O. Consensus on wound antisepsis: Update 2018. *SPP*, 2018; 31: 28-58.
173. Dayton P, Feilmeier M, and Sedberry S. Does postoperative showering or bathing of a surgical site increase the incidence of infection? A systematic review of the literature. *Foot Ankle Surg*, 2013; 52(5): 612-4.
174. Fernandez R and Griffiths R. Water for wound cleansing. *Cochrane Database Syst Rev*, 2012(2): N.PAG.
175. Huang CY and Choong MY. Comparison of wounds' infection rate between tap water and normal saline cleansing: A meta-analysis of randomised control trials. *Int Wound J*, 2019; 16(1): 300-1.
176. Queirós P, Santos E, Apóstolo J, Cardoso D, Cunha M, and Rodrigues M. The effectiveness of cleansing solutions for wound treatment: A systematic review. *JBI Database of Systematic Reviews & Implementation Report*, 2014; 12(10): 121-51.
177. Chan MC, Cheung K, and Leung P. Tap water versus sterile normal saline in wound swabbing: A double-blind randomized controlled trial. *J Wound Ostomy Continence Nurs*, 2016; 43(2): 140-7.
178. Lakshmi R, Andrews R, and Chumber S. A study to compare the effectiveness of normal saline vs tapwater in irrigation of chronic wounds. *International Journal of Nursing Education*, 2011; 3(1): 19-21.
179. Moscati RM, Mayrose J, Reardon RF, Janicke DM, and Jehle DV. A multicenter comparison of tap water versus sterile saline for wound irrigation. *Acad Emerg Med*, 2007; 14(5): 404-9.
180. Percival SL, Chen R, Mayer D, and Salisbury A-M. Mode of action of poloxamer-based surfactants in wound care and efficacy on biofilms. *Int Wound J*, 2018; 15(5): 749-55.
181. Ricci E. Cleansing versus tailored deep debridement, a fresh approach to wound cleansing: an Italian experience. *J Wound Care*, 2018; 27(8): 512-8.
182. Gouveia JCF, Miguéns CIM, Nogueira CLS, and Alves MIP. Is it safe to use saline solutions to clean wounds? *EWMA Journal*, 2007; 7(2): 7-12.
183. Dissemond J. Wound cleansing: Benefits of hypochlorous acid. *J Wound Care*, 2020; 29(Sup10a): S4-s8.
184. Liu JX, Werner JA, Buza JA, III, Kirsch T, Zuckerman JD, and Virk MS. Povidone-iodine solutions inhibit cell migration and survival of osteoblasts, fibroblasts, and myoblasts. *Spine (Phila Pa 1976)*, 2017; 42(23): 1757-62.
185. Wolcott RD, Cook RG, Johnson E, Jones CE, Kennedy JP, Simman R, Woo K, Weir D, Schultz G, and Hermans MH. A review of iodine-based compounds, with a focus on biofilms: Results of an expert panel. *J Wound Care*, 2020; 29(Sup7): S38-s43.
186. Alves PJ, Barreto RT, Barrois BM, Gryson LG, Meaume S, and Monstrey SJ. Update on the role of antiseptics in the management of chronic wounds with critical colonisation and/or biofilm. *Int Wound J*, 2020.
187. Barreto R, Barrois B, Lambert J, Malhotra-Kumar S, Santos-Fernandes V, and Monstrey S. Addressing the challenges in antisepsis: Focus on

- povidone iodine. *Int J Antimicrob Agents*, 2020; 56(3): 106064.
188. Dumville JC, Lipsky BA, Hoey C, Cruciani M, Fiscon M, and Xia J. Topical antimicrobial agents for treating foot ulcers in people with diabetes. *Cochrane Database Syst Rev*, 2017; 6(6): Cd011038.
  189. Tan EL and Johari NH. Comparative in vitro evaluation of the antimicrobial activities of povidone-iodine and other commercially available antiseptics against clinically relevant pathogens. *GMS Hyg Infect Control*, 2021; 16: Doc05.
  190. Carville K. *The Wound Care Manual* 2017. 7th ed. Perth, WA: Silver Chain.
  191. Isoherranen K, Jordan O'Brien J, Barker J, and al. e. 2019. EWMA document; Atypical wounds. Best clinical practice and challenges EWMA.
  192. Kwa KAA, Goei H, Breederveld RS, Middelkoop E, van der Vlies CH, and van Baar ME. A systematic review on surgical and nonsurgical debridement techniques of burn wounds. *J Plast Reconstr Aesthet Surg*, 2019; 72(11): 1752-62.
  193. Michailidis L, Bergin SM, Haines TP, and Williams CM. A systematic review to compare the effect of low-frequency ultrasonic versus nonsurgical sharp debridement on the healing rate of chronic diabetes-related foot ulcers. *Ostomy Wound Manage*, 2018; 64(9): 39-46.
  194. Shimada K, Ojima Y, Ida Y, and Matsumura H. Efficacy of Versajet hydrosurgery system in chronic wounds: A systematic review. *Int Wound J* 2021; 18(3): 269-78.
  195. Wormald JC, Wade RG, Dunne JA, Collins DP, and Jain A. Hydrosurgical debridement versus conventional surgical debridement for acute partial-thickness burns. *Cochrane Database Syst Rev*, 2020; 9: Cd012826.
  196. Elraiyah T, Domecq JP, Prutsky G, Tsapas A, Nabhan M, Frykberg RG, Hasan R, Firwana B, Prokop LJ, and Murad MH. A systematic review and meta-analysis of débridement methods for chronic diabetic foot ulcers. *J Vasc Surg*, 2016; 63(2 Suppl): 37S-45S.e1-2.
  197. Cowan T. Biofilms and their management: implications for the future of wound care. *J Wound Care*, 2010; 19(3): 117-20.
  198. Kim PJ, Attinger CE, Bigham T, Hagerty R, Platt S, Anghel E, Steinberg JS, and Evans KK. Clinic-based debridement of chronic ulcers has minimal impact on bacteria. *Wounds*, 2018; 30(5): 114-9.
  199. Tomaselli N. WOCN position statement. Conservative sharp wound debridement for registered nurses. *J Wound Ostomy Cont Nurs*, 1995; 22(1): 32A-4A.
  200. Mancini S, Cuomo R, Poggialini M, D'Aniello C, and Botta G. Autolytic debridement and management of bacterial load with an occlusive hydroactive deressing impregnated with polyhexamethylene biguanide. *Acta Biomed*, 2018; 88(4): 409-13.
  201. Meaume S, Dissemond J, Addala A, Vanscheidt W, Stücker M, Goerge T, Perceau G, Chahim M, Wicks G, Perez J, Tacca O, and Bohbot S. Evaluation of two fibrous wound dressings for the management of leg ulcers: results of a European randomised controlled trial (EARTH RCT). *J Wound Care*, 2014; 23(3): 105-16.
  202. Sterpione F, Mas K, Rippon M, Rogers A, Mayeux G, Rigaudier F, Chauvelot P, Robilliart L, Juhel C, and Lecomte Y. The clinical impact of hydroresponsive dressings in dynamic wound healing: Part I. *J Wound Care*, 2021; 30(1): 15-24.
  203. Bahr S, Mustafi N, Hättig P, Piatkowski A, Mosti G, Reimann K, Abel M, Dini V, Restelli J, Babadagi-Hardt Z, Abbritti F, Eberlein T, Wild T, and Bandl K. Clinical efficacy of a new monofilament fibre-containing wound debridement product. *J Wound Care*, 2011; 20(5): 242-8.
  204. Kataoka Y, Kunimitsu M, Nakagami G, Koudounas S, Weller CD, and Sanada H. Effectiveness of ultrasonic debridement on reduction of bacteria and biofilm in patients with chronic wounds: A scoping review. *Int Wound J*, 2021; 18(2): 176-86.
  205. Roes C, Calladine L, and Morris C. Biofilm management using monofilament fibre debridement technology: Outcomes and clinician and patient satisfaction. *J Wound Care*, 2019; 28(9): 608-22.
  206. Schultz GS, Woo K, Weir D, and Yang Q. Effectiveness of a monofilament wound debridement pad at removing biofilm and slough: Ex vivo and clinical performance. *J Wound Care*, 2018; 27(2): 80-90.
  207. Salehi SH, Momeni M, Vahdani M, and Moradi M. Clinical value of debriding enzymes as an adjunct to standard early surgical excision in human burns: A systematic review. *J Burn Care Res*, 2020; 41(6): 1224-30.
  208. Alberto EC, Cardenas L, Cipolle M, and Gallagher KE. Level 1 Trauma center experience utilizing negative pressure wound therapy with instillation: hypochlorous acid versus normal saline solution in complex or infected wounds. *Journal of Medical Science and Clinical Research*, 2020; 8(6).
  209. Campbell N and Campbell D. A retrospective, quality improvement review of maggot debridement therapy outcomes in a foot and leg ulcer clinic. *Ostomy Wound Manage*, 2014; 60(7): 16-25.
  210. Cowan LJ, Stechmiller JK, Phillips P, Yang Q, and Schultz G. Chronic wounds, biofilms and use of medicinal larvae. *Ulcers*, 2013; article 487024.
  211. Malekian A, Esmaeili Djavid G, Akbarzadeh K, Soltandallal M, Rassi Y, Rafinejad J, Rahimi Foroushani A, Farhoud A, Bakhtiary R, and Totonchi M. Efficacy of maggot therapy on *Staphylococcus aureus* and *Pseudomonas aeruginosa* in diabetic foot ulcers: A randomized controlled trial. *J Wound Ostomy Continence Nurs*, 2019; 46(1): 25-9.
  212. Watts R and Wound Healing and Management Node Group. Evidence Summary: Wound management: larval therapy. *Wound Practice and Research*, 2016; 24(3): 180-2.
  213. Mori Y, Nakagami G, Kitamura A, Minematsu T, Kinoshita M, Suga H, Kurita M, Hayashi C, Kawasaki A, and Sanada H. Effectiveness of biofilm-based wound care system on wound healing in chronic wounds. *Wound Repair and Regeneration*, 2019; 27(5): 540-7.
  214. Hiebert M. The postoperative effects of hypochlorous acid versus saline irrigation using ultrasound debridement on tissue bacterial wound counts in chronic open wounds patients. *Wound Repair Regen*, 2016; 24 (2): A10-A1.
  215. Johani K, Malone M, Jensen SO, Dickson HG, Gosbell IB, Hu H, Yang Q, Schultz G, and Vickery K. Evaluation of short exposure times of antimicrobial wound solutions against microbial biofilms: From in vitro to in vivo. *J Antimicrob Chemother*, 2018; 73(2): 494-502.
  216. Bellingeri A, Falciani F, Trapedini P, Moscatelli A, Russo A, Tino G, Chiari P, and Peghetti A. Effect of a wound cleansing solution on wound bed preparation and inflammation in chronic wounds: a single-blind RCT. *J Wound Care*, 2016; 25(3): 160, 2-6, 8.

217. Edwards-Jones V. Antimicrobial stewardship in wound care. *Br J Nus*, 2020; 29(15): S10-S9.
218. Lachapelle JM, Antiseptics and Disinfectants, in *Kanerva's Occupational Dermatology*, John SM, Johansen JD, Rustemeyer T, Elsner P, and Maibach H, Editors. 2020, Springer. p. 493-506.
219. Lineaweaver W, Howard R, Soucy D, McMorris S, Freeman J, Crain C, Robertson J, and . ea. Topical antimicrobial toxicity. *Arch Surg*, 1985; 120(3): 267-70.
220. Li Y-C, Kuan Y-H, Lee S-S, Huang F-M, and Chang Y-C. Cytotoxicity and genotoxicity of chlorhexidine on macrophages in vitro. *Environmental Toxicology*, 2014; 29(4): 452-8.
221. Punjataewakupt A, Napavichayanun S, and Aramwit P. The downside of antimicrobial agents for wound healing. *Eur J Clin Microbiol Infect Dis*, 2019; 38(1): 39-54.
222. Salami A, Imosemi I, and Owoeye O. A comparison of the effect of chlorhexidine, tap water and normal saline on healing wounds. *Int J Morphol*, 2006; 24(4): 673-6.
223. Brennan S and Leaper D. The effect of antiseptics on the healing wound: A study using the rabbit ear chamber. *BJS Open*, 1985; 72(10): 780-2.
224. De Smet K, van den Plas D, Lens D, and Sollie P. Pre-clinical evaluation of a new antimicrobial enzyme for the control of wound bioburden. *Wounds*, 2009; 21: 65–73.
225. Cooper RA. Inhibition of biofilms by glucose oxidase, lactoperoxidase and guaiacol: the active antibacterial component in an enzyme alginate. *Int Wound J*, 2013; 10(6): 630-7.
226. White RJ. Flaminal enzyme alginate: A novel approach to the control of wound exudate, bioburden and debridement. *J Tissue Viability*, 2014; 23(2): 78-80.
227. Woo K, Hill R, LeBlanc K, Percival SL, Schultz G, Weir D, Swanson T, and Mayer DO. Effect of a surfactant-based gel on patient quality of life. *J Wound Care*, 2018; 27(10): 664-78.
228. Bezza FA, Tichapondwa SM, and Chirwa EMN. Fabrication of monodispersed copper oxide nanoparticles with potential application as antimicrobial agents. *Scientific Reports*, 2020; 10(1): 16680.
229. Ahamed M, Alhadlaq HA, Khan MAM, Karuppiyah P, and Al-Dhabi NA. Synthesis, characterization, and antimicrobial activity of copper oxide nanoparticles. *Journal of Nanomaterials*, 2014; 2014: 637858.
230. Balcucho J, Narváez DM, and Castro-Mayorga JL. Antimicrobial and biocompatible polycaprolactone and copper oxide nanoparticle wound dressings against methicillin-resistant *Staphylococcus aureus*. *Nanomaterials*, 2020; 10(9).
231. Ronner AC, Curtin J, Karami N, and Ronner U. Adhesion of methicillin-resistant *Staphylococcus aureus* to DACC-coated dressings. *J Wound Care*, 2014; 23(10): 484-8.
232. Cooper R and Jenkins L. Binding of two bacterial biofilms to dialkyl carbamoyl chloride (DACC)-coated dressings *J Wound Care*, 2016; 25(2): 76-82.
233. Rippon MG, Rogers AA, and Ousey K. Antimicrobial stewardship strategies in wound care: Evidence to support the use of dialkylcarbamoyl chloride (DACC)- coated wound dressings. *J Wound Care*, 2021; 30(4): 284-96.
234. Mosti G, Magliaro A, Mattaliano V, Picerni P, and Angelotti N. Comparative study of two antimicrobial dressings in infected leg ulcers: A pilot study. *J Wound Care*, 2015; 24(3): 121-7.
235. Totty JP, Bua N, Smith GE, Harwood AE, Carradice D, Wallace T, and Chetter IC. Dialkylcarbamoyl chloride (DACC)-coated dressings in the management and prevention of wound infection: a systematic review. *J Wound Care*, 2017; 26(3): 107-14.
236. National Institute of Health and Care Excellence. 2021. Leukomed Sorbact for preventing surgical site infection, NICE Guidance NICE: UK.
237. Yilmaz AC and Aygin D. Honey dressing in wound treatment: A systematic review. *Complement Ther Med*, 2020; 51.
238. McLoone P, Tabys D, and Fyfe L. Honey combination therapies for skin and wound Infections: A systematic review of the literature. *Clin Cosmet Investig Dermatol*, 2020; 13: 875-88.
239. Mama M, Teshome T, and Detamo J. Antibacterial activity of honey against methicillin-resistant *Staphylococcus aureus*: A laboratory-based experimental study. *Int J Microbiol*, 2019; 2019: 7686130.
240. Girma A, Seo W, and She RC. Antibacterial activity of varying UMF-graded Manuka honeys. *PLoS One*, 2019; 14(10): e0224495.
241. Pleeging CCF, Coenye T, Mossialos D, de Rooster H, Chrysostomou D, Wagener F, and Cremers NAJ. Synergistic antimicrobial activity of supplemented medical-grade honey against *Pseudomonas aeruginosa* biofilm formation and eradication. *Antibiotics (Basel)*, 2020; 9(12).
242. Halstead FD, Webber MA, and Oppenheim BA. Use of an engineered honey to eradicate preformed biofilms of important wound pathogens: an in vitro study. *J Wound Care*, 2017; 26(8): 442-50.
243. Cooper RA, Bjarnsholt T, and Alhede M. Biofilms in wounds: a review of present knowledge. *J Wound Care*, 2014; 23(11): 570-80.
244. Lu J, Turnbull L, Burke CM, Liu M, Carter DA, Schlothauer RC, Whitchurch CB, and Harry EJ. Manuka-type honeys can eradicate biofilms produced by *Staphylococcus aureus* strains with different biofilm-forming abilities. *PeerJ*, 2014; 2: e326.
245. Oryan A, Alemzadeh E, and Moshiri A. Biological properties and therapeutic activities of honey in wound healing: A narrative review and meta-analysis. *J Tissue Viability*, 2016; 25(2): 98-118.
246. Mitani O, Nishikawa A, Kurokawa I, Gabazza EC, Ikeda M, and Mizutani H. Enhanced wound healing by topical application of ointment containing a low concentration of povidone-iodine. *J Wound Care*, 2016; 25(9): 521-9.
247. Malone M, Johani K, Jensen SO, Gosbell IB, Dickson HG, McLennan S, Hu H, and Vickery K. Effect of cadexomer iodine on the microbial load and diversity of chronic non-healing diabetic foot ulcers complicated by biofilm in vivo. *J Antimicrob Chemother*, 2017; 72(7): 2093-101.
248. Schwarzer S, James GA, Goeres D, Bjarnsholt T, Vickery K, Percival SL, Stoodley P, Schultz G, Jensen SO, and Malone M. The efficacy of



- topical agents used in wounds for managing chronic biofilm infections: A systematic review. *J Infect*, 2020; 80(3): 261-70.
249. Kida D, Gładysz O, Szulc M, Zborowski J, Junka A, Janeczek M, Lipińska A, Skalec A, and Karolewicz B. Development and evaluation of a polyvinylalcohol-cellulose derivative-based film with povidone-iodine predicted for wound treatment. *Polymers (Basel)*, 2020; 12(6).
  250. Yonezawa R, Sunaga T, Maruoka J, Kadomatsu K, and Watanabe T. A case of iodoform toxicity due to drug-induced acute kidney injury after discontinuation of iodoform gauze. *Am J Ther*, 2021.
  251. Cutting KF, White RJ, and Mahoney P. Wound infection, dressings and pain, is there a relationship in the chronic wound? *Int Wound J*, 2013; 10(1): 79-86.
  252. Kramer A and Assadian O. Octenidine dihydrochloride-Characteristics and clinical use. *Int J Antimicrob Agents*, 2013; 42: S21.
  253. Krishna BVS and Gibb AP. Use of octenidine dihydrochloride in meticillin-resistant *Staphylococcus aureus* decolonisation regimens: A literature review. *J Hosp Infect*, 2010; 74(3): 199-203.
  254. Staneviciute E, Na'amnih W, Kavaliauskas P, Prakapaitė R, Ridziauskas M, Kevlicius L, Kirkliauskiene A, Zabulis V, Urboniene J, and Triponis V. New in vitro model evaluating antiseptics' efficacy in biofilm-associated *Staphylococcus aureus* prosthetic vascular graft infection. *J Med Microbiol*, 2019; 68(3): 432-9.
  255. Hirsch T, Limoochi-Deli S, Lahmer A, Jacobsen F, Goertz O, Steinau HU, Seipp HM, and Steinstreasser L. Antimicrobial activity of clinically used antiseptics and wound irrigating agents in combination with wound dressings. *Plast Reconstr Surg*, 2011; 127(4): 1539-45.
  256. Goroncy-Bermes P, Brill FHH, and Brill H. Antimicrobial activity of wound antiseptics against extended-spectrum beta-lactamase-producing bacteria. *Wound Medicine*, 2013; 1: 41-3.
  257. Assadian O. Octenidine dihydrochloride: chemical characteristics and antimicrobial properties. *J Wound Care*, 2016; 25(3 Suppl): S3-6.
  258. Pavlik V, Sojka M, Mazurova M, and Velebny V. Dual role of iodine, silver, chlorhexidine and octenidine as antimicrobial and antiprotease agents. *PLoS One*, 2019; 14(1).
  259. Krasowski G, Junka A, Paleczny J, Czajkowska J, Makomaska-Szaroszyk E, Chodaczek G, Majkowski M, Migdał P, Fijałkowski K, Kowalska-Krochmal B, and Bartoszewicz M. In vitro evaluation of polihexanide, octenidine and NaClO/HClO-based antiseptics against biofilm formed by wound pathogens. *Membranes (Basel)*, 2021; 11(1).
  260. Stuermer EK, Besser M, Brill F, Geffken M, Plattfaut I, Severing AL, Wiencke V, Rembe JD, Naumova EA, Kampe A, Debus S, and Smeets R. Comparative analysis of biofilm models to determine the efficacy of antimicrobials. *Int J Hyg Environ Health*, 2021; 234: 113744.
  261. Braun M, McGrath A, and Downie F. Octenilin® range made easy. *Wounds UK*, 2013; 9(4).
  262. Hämmerle G and Strohal R. Efficacy and cost-effectiveness of octenidine wound gel in the treatment of chronic venous leg ulcers in comparison to modern wound dressings. *Int Wound J*, 2016; 13(2): 182-8.
  263. Haesler E. Evidence Summary: Octenidine for chronic wounds. *Wound Practice and Research*, 2020; 28(1): 42-4.
  264. Muller-Wirth N, Pichler WJ, and Hausmann O. A case of severe anaphylaxis to octenidine: In vitro cross-reactivity to antiseptics containing hexamethylene residues. *Clinical and Translational Allergy. Conference: 8th Drug Hypersensitivity Meeting, DHM*, 2018; 8(Supplement 3).
  265. Holdrowicz A, Narbutt J, Palczynski C, Kuprys-Lipinska I, and Lesiak A. Bullous skin lesion reaction as an example of an adverse effect of a preparation containing 0.1% octenidine dihydrochloride and 2% phenoxyethanol (Octenisept). *Przegląd Dermatologiczny*, 2018; 105(6): 753-60.
  266. Hübner NO and Kramer A. Review on the efficacy, safety and clinical applications of polihexanide, a modern wound antiseptic. *Skin Pharmacol Physiol*, 2010; 23(Suppl 1): 17-27.
  267. McMahon RE, Salamone AB, Poleon S, Bionda N, and Salamone JC. Efficacy of wound cleansers on wound-specific organisms using in vitro and ex vivo biofilm models. *Wound Manag Prev*, 2020; 66(11): 31-42.
  268. Davis SC, Harding A, Gil J, Parajon F, Valdes J, Solis M, and Higa A. Effectiveness of a polyhexanide irrigation solution on methicillin-resistant *Staphylococcus aureus* biofilms in a porcine wound model. *Int Wound J*, 2017; 14(6): 937-44.
  269. Salisbury AM, Mullin M, Chen R, and Percival SL. Antibiofilm efficacy of polihexanide, octenidine and sodium hypochlorite/hypochlorous acid based wound irrigation solutions against *Staphylococcus aureus*, *Pseudomonas aeruginosa* and a multispecies biofilm. *Adv Exp Med Biol*, 2021.
  270. Roberto B, Simone T, Giuseppina G, Elisa C, Francesca M, and Claudia S. Local control of bioburden and infection, in mdrb. *Journal of Wound Care*, 2020; 29 (SUPPL 7B): 276.
  271. Dissemond J, Steinmann J, Münter KC, Brill H, Böttrich JG, Braunwarth H, Schümmelfeder F, and Wilken P. Risk and clinical impact of bacterial resistance/susceptibility to silver-based wound dressings: A systematic review. *J Wound Care*, 2020; 29(4): 221-34.
  272. Hosny AEDMS, Rasmy SA, Aboul-Magd DS, Kashef MT, and El-Bazza ZE. The increasing threat of silver-resistance in clinical isolates from wounds and burns. *Infect Drug Resist*, 2019; 12: 1985-2001.
  273. Krishnan PD, Banas D, Durai RD, Kabanov D, Hosnedlova B, Kepinska M, Fernandez C, Ruttkay-Nedecky B, Nguyen HV, Farid A, Sochor J, Narayanan VHB, and Kizek R. Silver nanomaterials for wound dressing applications. *Pharmaceutics*, 2020; 12(9).
  274. Capanema NSV, Mansur AAP, Carvalho SM, Mansur LL, Ramos CP, Lage AP, and Mansur HS. Physicochemical properties and antimicrobial activity of biocompatible carboxymethylcellulose-silver nanoparticle hybrids for wound dressing and epidermal repair. *J Appl Polymer Science*, 2018; 135(6): 45812.
  275. Myronov P, Sulaieva O, Korniienko V, Banasiuk R, Vielikov M, Husak Y, Pernakov M, Deineka V, Yusupova A, Hristova MT, Savchenko A, Holubnycha V, and Pogorielov M. Combination of chlorhexidine and silver nanoparticles: An efficient wound infection and healing control system. *BioNanoScience*, 2021; 11(2): 256-68.
  276. Bowler PG and Parsons D. Combatting wound biofilm and recalcitrance with a novel anti-biofilm Hydrofiber wound dressing. *Wound Medicine* 2016; 14(6-11).

277. Furtado K, Siaw-Sakyi V, and Bowler P. 2019. More than Silver(TM) Technology Made Easy. *Wounds International*.
278. Finnegan S and Percival SL. EDTA: An antimicrobial and antibiofilm agent for use in wound care. *Adv Wound Care*, 2015; 4(7): 415-21.
279. Mishra B, Sharma DJ, and Arora C. Comparative study of the efficacy of ionic silver solution and super oxidized solution in the management of chronic wounds. *Med J Armed Forces India*, 2021.
280. Severing AL, Rembe JD, Koester V, and Stuermer EK. Safety and efficacy profiles of different commercial sodium hypochlorite/hypochlorous acid solutions (NaClO/HClO): Antimicrobial efficacy, cytotoxic impact and physicochemical parameters in vitro. *J Antimicrob Chemother*, 2019; 74(2): 365-72.
281. Schultz G, Weir D, Ruotsi L, Black J, Desvigne M, Fernandez LG, Couch K, and Rodeheaver GT. Clinical efficacy of pure hypochlorous acid preservative-based wound solutions *Wound Source*, 2021; 11(29).
282. Harriott MM, Bhindi N, Kassis S, Summitt B, Perdakis G, Wormer BA, Rankin TM, Kaoutzanis C, Samaha M, Stratton C, and Schmitz JE. Comparative antimicrobial activity of commercial wound care solutions on bacterial and fungal biofilms. *Ann Plast Surg*, 2019; 83(4): 404-10.
283. Wiegand C, Abel M, Ruth P, Elsner P, and Hipler UC. pH influence on antibacterial efficacy of common antiseptic substances. *Skin Pharmacol Physiol*, 2015; 28(3): 147-58.
284. Norman G, Christie J, Liu Z, Westby MJ, Jefferies JM, Hudson T, Edwards J, Mohapatra DP, Hassan IA, and Dumville JC. Antiseptics for burns. *Cochrane Database Syst Rev*, 2017; 7(7): Cd011821.
285. Norman G, Dumville JC, Mohapatra DP, Owens GL, and Crosbie EJ. Antibiotics and antiseptics for surgical wounds healing by secondary intention. *Cochrane Database Syst Rev*, 2016; 2016(3).
286. Norman G, Dumville JC, Moore ZE, Tanner J, Christie J, and Goto S. Antibiotics and antiseptics for pressure ulcers. *Cochrane Database Syst Rev*, 2016; 2016(4).
287. Norman G, Westby MJ, Rithalia AD, Stubbs N, Soares MO, and Dumville JC. Dressings and topical agents for treating venous leg ulcers. *Cochrane Database Syst Rev*, 2018; 6(6): Cd012583.
288. To E, Dyck R, Gerber S, Kadavil S, and Woo KY. The effectiveness of topical polyhexamethylene biguanide (PHMB) agents for the Treatment of chronic wounds: A systematic review. *Surg Technol Int*, 2016; 29: 45-51.
289. Rashaan ZM, Krijnen P, Kwa KAA, van der Vlies CH, Schipper IB, and Breederveld RS. Flaminal® versus Flamazine® in the treatment of partial thickness burns: A randomized controlled trial on clinical effectiveness and scar quality (FLAM study). *Wound Repair Regen*, 2019; 27(3): 257-67.
290. O'Meara S, Al-Kurdi D, Ologun Y, Ovington LG, Martyn-St James M, and Richardson R. Antibiotics and antiseptics for venous leg ulcers. *Cochrane Database Syst Rev*, 2014(1): Cd003557.
291. Woo K, Dowsett C, Costa B, Ebohon S, Woodmansey EJ, and Malone M. Efficacy of topical cadexomer iodine treatment in chronic wounds: Systematic review and meta-analysis of comparative clinical trials. *Int Wound J*, 2021.
292. Raju R, Kethavath SN, Sangavarapu SM, and Kanjarla P. Efficacy of cadexomer iodine in the treatment of chronic ulcers: A Randomized, multicenter, controlled trial. *Wounds*, 2019; 31(3): 85-90.
293. Romain B, Mielcarek M, Delhorme JB, Meyer N, Brigand C, Rohr S, and group S. Dialkylcarbamoyl chloride-coated versus alginate dressings after pilonidal sinus excision: A randomized clinical trial (SORKYSA study). *BJs open*, 2020; 4(2): 225-31.
294. Aziz Z and Abdul Rasool Hassan B. The effects of honey compared to silver sulfadiazine for the treatment of burns: A systematic review of randomized controlled trials. *Burns*, 2017; 43(1): 50-7.
295. Jull AB, Cullum N, Dumville JC, Westby MJ, Deshpande S, and Walker N. Honey as a topical treatment for wounds. *Cochrane Database Syst Rev*, 2015(3): Cd005083.
296. Vanscheidt W, Harding K, Téot L, and Siebert J. Effectiveness and tissue compatibility of a 12-week treatment of chronic venous leg ulcers with an octenidine based antiseptic-A randomized, double-blind controlled study. *Int Wound J*, 2012; 9(3): 316-23.
297. Frew Q, Rennekampff HO, Dziwulski P, Moiemien N, Zahn T, and Hartmann B. Betulin wound gel accelerated healing of superficial partial thickness burns: Results of a randomized, intra-individually controlled, phase III trial with 12-months follow-up. *Burns*, 2019; 45(4): 876-90.
298. Eberlein T, Haemmerle G, Signer M, Gruber Moesenbacher U, Traber J, Mittlboeck M, Abel M, and Strohal R. Comparison of PHMB-containing dressing and silver dressings in patients with critically colonised or locally infected wounds. *J Wound Care*, 2012; 21(1): 12, 4-6, 8-20.
299. Gwak HC, Han SH, Lee J, Park S, Sung KS, Kim HJ, Chun D, Lee K, Ahn JH, Kwak K, and Chung HJ. Efficacy of a povidone-iodine foam dressing (Betafoam) on diabetic foot ulcer. *Int Wound J*, 2020; 17(1): 91-9.
300. Pak CS, Park DH, Oh TS, Lee WJ, Jun YJ, Lee KA, Oh KS, Kwak KH, and Rhie JW. Comparison of the efficacy and safety of povidone-iodine foam dressing (Betafoam), hydrocellular foam dressing (Allevyn), and petrolatum gauze for split-thickness skin graft donor site dressing. *Int Wound J*, 2019; 16(2): 379-86.
301. Parikh R, Bakhshi G, Naik M, Gaikwad B, Jadhav K, and Tayade M. The efficacy and safety of tetrachlorodecaoxide in comparison with super-oxidised solution in wound healing. *Arch Plast Surg*, 2016; 43(5): 395-401.
302. Eftekhariadeh F, Dehnavieh R, Noori Hekmat S, and Mehrolihasani MH. Health technology assessment on super oxidized water for treatment of chronic wounds. *Med J Islam Repub Iran*, 2016; 30: 384.
303. Haesler E. Evidence Summary: Super-oxidised solutions for chronic wounds. *Wound Practice and Research*, 2020; 28(3): 145-7.
304. Piaggese A, Goretti C, Mazzurco S, Tascini C, Leonildi A, Rizzo L, Tedeschi A, Gemignani G, Menichetti F, and Del Prato S. A randomized controlled trial to examine the efficacy and safety of a new super-oxidized solution for the management of wide postsurgical lesions of the diabetic foot. *Int J Low Extrem Wounds*, 2010; 9(1): 10-5.

305. Nherera L, Trueman P, Roberts C, and Berg L. Silver delivery approaches in the management of partial thickness burns: A systematic review and indirect treatment comparison. *Wound Repair Regen*, 2017; 25(4): 707-21.
306. Dissemond J, Böttrich JG, Braunwarth H, Hilt J, Wilken P, and Münter KC. Evidence for silver in wound care - Meta-analysis of clinical studies from 2000-2015. *J Dtsch Dermatol Ges*, 2017; 15(5): 524-35.
307. Tsang KK, Kwong EWY, To TSS, Chung JWY, and Wong TKS. A pilot randomized, controlled study of nanocrystalline silver, manuka honey, and conventional dressing in healing diabetic foot ulcer. *Evid Based Complement Alternat Med*, 2017; 2017 (no pagination).
308. Heyneman A, Hoeksema H, Vandekerckhove D, Pirayesh A, and Monstrey S. The role of silver sulphadiazine in the conservative treatment of partial thickness burn wounds: A systematic review. *Burns*, 2016; 42(7): 1377-86.
309. Maciel A, Ortiz JF, Siqueira BS, and Zanette GF. Tissue healing efficacy in burn patients treated with 1% silver sulfadiazine versus other treatments: A systematic review and meta-analysis of randomized controlled trials. *An Bras Dermatol*, 2019; 94(2): 204-10.
310. Wang C, Guo M, Zhang N, and Wang G. Effectiveness of honey dressing in the treatment of diabetic foot ulcers: A systematic review and meta-analysis. *Complement Ther Clin Pract*, 2019; 34: 123-31.
311. Assadian O, Kammerlander G, Geyrhofer C, Luch G, Doppler S, Tuchmann F, Eberlein T, and Leaper D. Use of wet-to-moist cleansing with different irrigation solutions to reduce bacterial bioburden in chronic wounds. *J Wound Care*, 2018; 27(Sup10): S10-s6.
312. Wattanaploy S, Chinaronchai K, Namviriyachote N, and Muangman P. Randomized controlled trial of polyhexanide/betaine gel versus silver sulfadiazine for partial-thickness burn treatment. *Int J Low Extrem Wounds*, 2017; 16(1): 45-50.
313. Payne B, Simmen HP, Csuka E, Hintzpeter M, Pahl S, and Brill FHH. Randomized controlled clinical trial on the antiseptic efficacy of polihexanide 0.04% on acute traumatic wounds. *J Hosp Infect*, 2018; 98(4): 429-32.
314. Ghafouri HB, Zavareh M, Jalili F, and Cheraghi S. Is 1% povidone-iodine solution superior to normal saline for simple traumatic wound irrigation? *Wound Medicine*, 2016; 15: 1-5.
315. Hiebert JM and Robson MC. The immediate and delayed post-debridement effects on tissue bacterial wound counts of hypochlorous acid versus saline irrigation in chronic wounds. *Eplasty*, 2016; 16: e32.
316. Nherera LM, Trueman P, Roberts CD, and Berg L. A systematic review and meta-analysis of clinical outcomes associated with nanocrystalline silver use compared to alternative silver delivery systems in the management of superficial and deep partial thickness burns. *Burns*, 2017; 43(5): 939-48.
317. Malone M, Schwarzer S, Radzieta M, Jeffries T, Walsh A, Dickson HG, Micali G, and Jensen SO. Effect on total microbial load and community composition with two vs six-week topical cadexomer iodine for treating chronic biofilm infections in diabetic foot ulcers. *Int Wound J*, 2019; 16(6): 1477-86.
318. Stanirowski PJ, Bizoń M, Cendrowski K, and Sawicki W. Randomized controlled trial evaluating dialkylcarbamoyl chloride impregnated dressings for the prevention of surgical site infections in adult women undergoing cesarean section. *Surg Infect (Larchmt)*, 2016; 17(4): 427-35.
319. Meberg A and Schøyen R. Hydrophobic material in routine umbilical cord care and prevention of infections in newborn infants. *Scand J Infect Dis*, 1990; 22(6): 729-33.
320. Bua N, Smith GE, Totty JP, Pan D, Wallace T, Carradice D, and Chetter IC. Dialkylcarbamoyl chloride dressings in the prevention of surgical site infections after nonimplant vascular surgery. *Ann Vasc Surg*, 2017; 44: 387-92.
321. Radu CA, Gazyakan E, Germann G, Riedel K, Reichenberger M, and Ryssel H. Optimizing Suprathel®-therapy by the use of Octenidine-Gel®. *Burns*, 2011; 37(2): 294-8.
322. Borges EL, Frison SS, Honorato-Sampaio K, Guedes ACM, Lima V, Oliveira OMM, Ferraz AF, and Tyrone AC. Effect of polyhexamethylene biguanide solution on bacterial load and biofilm in venous leg ulcers: A Randomized controlled trial. *J Wound Ostomy Continence Nurs*, 2018; 45(5): 425-31.
323. Lo S-F, Chang C-J, Hu W-Y, Hayter M, and Chang Y-T. The effectiveness of silver-releasing dressings in the management of non-healing chronic wounds: A meta-analysis. *J Clin Nurs*, 2009; 18(5): 716-28.
324. Foster KN, Richey KJ, Champagne JS, and Matthews MR. Randomized Comparison of Hypochlorous Acid With 5% Sulfamylon Solution as Topical Therapy Following Skin Grafting. *Eplasty*, 2019; 19: e16.
325. Ayello EA, Carville K, Fletcher J, Keast DH, Leaper D, Lindholm C, Martinez JLL, Mavanani S, McBain A, Moore Z, Opananon S, and Pina E. 2012. Appropriate use of silver dressings in wounds: A expert working group consensus. *Wounds International*: London.
326. Chaplin S. NICE on antimicrobial prescribing for leg ulcer infection. *Prescriber*, 2020; 31(7-8): 27-30.
327. Tong QJ, Hammer KD, Johnson EM, Zegarra M, Goto M, and Lo TS. A systematic review and meta-analysis on the use of prophylactic topical antibiotics for the prevention of uncomplicated wound infections. *Infect Drug Resist*, 2018; 11: 417-25.
328. Marson BA, Deshmukh SR, Grindlay DJC, Ollivere BJ, and Scammell BE. A systematic review of local antibiotic devices used to improve wound healing following the surgical management of foot infections in diabetics. *Bone Joint J*, 2018; 100-b(11): 1409-15.
329. Paul JC and Piper BA. Topical metronidazole for the treatment of wound odor: A review of the literature. *Ostomy Wound Manage* 2008; 54(3): 18-27.
330. Ramage G, Robertson SN, and Williams C. Strength in numbers: antifungal strategies against fungal biofilms. *Int J Antimicrob Agents*, 2014; 43(2): 114-20.
331. Horvath EE, Murray CK, Vaughan GM, Chung KK, Hospenthal DR, and Wade CE. Fungal wound infection (not colonization) is independently associated with mortality in burn patients. *Ann Surg*, 2007; 245: 978-85.
332. Rodriguez N, Finnerty C, Calhoun B, Hawkins H, and Herndon D. Fungal wound invasion is associated with increased mortality in pediatric burn patients, in *Surgical Infections. Conference: 32nd Annual Meeting of the Surgical Infection Society 2012*: Dallas, TX United States. p.

333. Coleman K and Neilsen G. *Wound Care: A practical guide for maintaining skin integrity*. 2020. Chatswood, NSW: Elsevier Australia.
334. Palmer SJ. Practising asepsis during dressing changes in community settings. *Br J Community Nurs*, 2019; 24(12): 600-3.
335. Parker L. Applying the principles of infection control to wound care. *Br J Nurs*, 2000; 9(7): 394-400.
336. National Health and Medical Research Council. 2019. *Australian Guidelines for the Prevention and Control of Infection in Healthcare*. NHMRC: Canberra.
337. WOCN Wound Committee. Clean vs. sterile dressing techniques for management of chronic wounds: A fact sheet. *J Wound Ostomy Continence Nurs*, 2012; 39(2S): S30-s4.
338. Wounds Australia. 2020. *Application of aseptic technique in wound dressing procedure: A consensus document*. Third Edition. Wounds Australia: ACT.
339. Templeton S, Wong C, Rando T, Adamson P, and Lynn P. Microbial contamination of open-but-unused portions of wound dressings stored in home settings. *International Wound Journal*, 2018; 15(1): 106-13.
340. Haesler E, Thomas L, Morey P, and Barker J. A systematic review of the literature addressing asepsis in wound management. *Wound Practice and Research*, 2016; 24(4): 208-16.
341. Gould DJ, Chudleigh J, Purssell E, Hawker C, Gaze S, James D, Lynch M, Pope N, and Drey N. Survey to explore understanding of the principles of aseptic technique: Qualitative content analysis with descriptive analysis of confidence and training. *Am J Infect Control*, 2018; 46(4): 393-6.
342. World Health Organization (WHO). 2020. *Antimicrobial resistance fact sheet*. WHO: <https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance>.
343. Edwards-Jones V. Antimicrobial resistance—challenges for the 21st century. *Wounds UK*, 2018; 14(3): 46–51.
344. World Health Organization (WHO). 2019. *Antimicrobial stewardship programmes in health-care facilities in low- and middle-income countries. A practical toolkit*. WHO: Geneva.
345. D’Atri F, Arthur J, Blix HS, Hicks LA, Plachouras D, Monnet DL, and Group tESoTTFoARTA. Targets for the reduction of antibiotic use in humans in the Transatlantic Taskforce on Antimicrobial Resistance (TATFAR) partner countries. *Euro Surveill*, 2019; 24(28).
346. Roberts C, Leaper D, and Assadian O. The role of topical antiseptic agents within antimicrobial stewardship strategies for prevention and treatment of surgical site and chronic open wound infection. *Adv Wound Care*, 2017; 6(2): 63-71.
347. O’Neill J. 2016. *Tackling Drug-Resistant Infections Globally: Final Report and Recommendations: the Review on Antimicrobial Resistance*. UK Government Department of Health and Wellcome Trust: UK.
348. Blaser MJ, Melby MK, Lock M, and Nichter M. Accounting for variation in and overuse of antibiotics among humans. *Bioessays*, 2021; 43(2): e2000163.
349. Waldrop RD, Prejean C, and Singleton R. Overuse of parenteral antibiotics for wound care in an urban emergency department. *Am J Emerg Med*, 1998; 16(4): 343-5.
350. Price N. Routine fluorescence imaging to detect wound bacteria reduces antibiotic use and antimicrobial dressing expenditure while improving healing rates: Retrospective analysis of 229 foot ulcers. *Diagnostics*, 2020; 10(11): 927.
351. The Association for Professionals in Infection Control and Epidemiology (APIC). *Antimicrobial stewardship*. 2021. [cited June 2021]; Available from: <https://apic.org/Professional-Practice/Practice-Resources/Antimicrobial-Stewardship/>.
352. Centers for Disease Control and Prevention. *Transatlantic Taskforce on Antimicrobial Resistance (TATFAR)*. 2021. [cited July 2021]; Available from: <https://www.cdc.gov/drugresistance/tatfar/index.html>.
353. *Transatlantic Taskforce on Antimicrobial Resistance*. 2011. *Transatlantic Taskforce on Antimicrobial Resistance*. CDC: <https://www.cdc.gov/drugresistance/pdf/tatfar-report.pdf>.
354. *Transatlantic Taskforce on Antimicrobial Resistance*. 2014. *Transatlantic Taskforce on Antimicrobial Resistance: Progress report* CDC: [https://www.cdc.gov/drugresistance/pdf/tatfar-progress\\_report\\_2014.pdf](https://www.cdc.gov/drugresistance/pdf/tatfar-progress_report_2014.pdf).
355. *Global Antibiotic Resistance Partnership (GARP) Network*. *Global Antibiotic Resistance Partnership (GARP)*. 2021. [cited July 2021]; Available from: <https://cddep.org/projects/global-antibiotic-resistance-partnership/>.
356. Gelband H and Miller-Petrie M. 2016. *GARP Global Overview*. Center for Disease Dynamics, Economics and Policy and Global Antibiotic Resistance Partnership: [https://cddep.org/wp-content/uploads/2017/06/garp\\_global\\_overview.pdf](https://cddep.org/wp-content/uploads/2017/06/garp_global_overview.pdf).
357. *Global Health Security Agenda. Antimicrobial Resistance*. 2020. [cited July 2021]; Available from: <https://ghsagenda.org/antimicrobial-resistance/>.
358. *Joint Programming Initiative on Antimicrobial Resistance. Global Coordination of Antimicrobial Resistance Research*. 2021. [cited July 2021]; Available from: <https://www.jpamr.eu/>.
359. Food and Agriculture Organization of the United Nations (FAO), World Health Organization (WHO), and World Organisation for Animal Health (OIE). 2017. *The Tripartite’s Commitment: Providing multi-sectoral, collaborative leadership in addressing health challenges*. FAO, WHO and OIE: [https://www.who.int/zoonoses/tripartite\\_oct2017.pdf](https://www.who.int/zoonoses/tripartite_oct2017.pdf).
360. World Health Organization (WHO). *World Antimicrobial Awareness Week 2020 - Handle with care: United to preserve antimicrobials*. 2020. [cited July 2021]; Available from: <https://www.who.int/news-room/events/detail/2020/11/18/default-calendar/world-antimicrobial-awareness-week-2020>.
361. Pulcini C, Beovic B, Howard P, and Mendelson M. Human resources estimates and funding for antibiotic stewardship teams are urgently needed: authors' response. *Clin Microbiol Infect*, 2018; 24(5): 557.

362. Woodmansey EJ and Roberts CD. Appropriate use of dressings containing nanocrystalline silver to support antimicrobial stewardship in wounds. *Int Wound J* 2018; 15(6): 1025-32.
363. World Union of Wound Healing Societies. 2020. The role of non-medicated dressings for the management of wound infection. *Wounds International*: London.
364. Ousey K and Blackburn J. Understanding antimicrobial resistance and antimicrobial stewardship in wound management. *Wounds UK*, 2020; 16(2): 36-9.
365. Cooper R and Kirketerp-Møller K. Non-antibiotic antimicrobial interventions and antimicrobial stewardship in wound care. *J Wound Care*, 2018; 27(6): 355-77.
366. Wilkinson A, Ebata A, and MacGregor H. Interventions to reduce antibiotic prescribing in LMICs: A scoping review of evidence from human and animal health systems. *Antibiotics (Basel)*, 2018; 8(1): 2.
367. Maillard J-Y, Kampf G, and Cooper R. Antimicrobial stewardship of antiseptics that are pertinent to wounds: the need for a united approach. *JAC Antimicrob Resist*, 2021; 3(1).
368. Coenye T, Kjellerup B, Stoodley P, and Bjarnsholt T. The future of biofilm research – Report on the ‘2019 Biofilm Bash’. *Biofilm*, 2020; 2: 100012.
369. Metcalf DG, Haalboom M, Bowler PG, Gamerith C, Sigl E, Heinzle A, and Burnet MWM. Elevated wound fluid pH correlates with increased risk of wound infection. *Wound Medicine*, 2019; 26(1): 100166.
370. Blackshaw EL and Jeffery SLA. Efficacy of an imaging device at identifying the presence of bacteria in wounds at a plastic surgery outpatients clinic. *J Wound Care*, 2018; 27(1): 20-6.
371. Hurley CM, McClusky P, Sugrue RM, Clover JA, and Kelly JE. Efficacy of a bacterial fluorescence imaging device in an outpatient wound care clinic: a pilot study. *J Wound Care*, 2019; 28(7): 438-43.
372. Raizman R, Little W, and Smith AC. Rapid diagnosis of *Pseudomonas aeruginosa* in wounds with point-of-care fluorescence imaging. *Diagnostics (Basel)*, 2021; 11(2).
373. Serena TE. Incorporating point-of-care bacterial fluorescence into a wound clinic antimicrobial stewardship program *Diagnostics*, 2020; 10(12): 1010.
374. Le L, Baer M, Briggs P, Bullock N, Cole W, DiMarco D, Hamil R, Harrell K, Kasper M, Li W, Patel K, Sabo M, Thibodeaux K, and Serena TE. Diagnostic accuracy of point-of-care fluorescence imaging for the detection of bacterial burden in wounds: Results from the 350-patient fluorescence imaging assessment and guidance trial. *Adv Wound Care (New Rochelle)*, 2021; 10(3): 123-36.
375. Rennie MY, Dunham D, Lindvere-Teene L, Raizman R, Hill R, and Linden R. Understanding real-time fluorescence signals from bacteria and wound tissues observed with the MolecuLight i:XTM. *Diagnostics*, 2019; 9(1): 22.
376. Rennie MY, Teene L, Manor R, Serena T, and Jones L. Fluorescence imaging and delayed healing are the only significant predictors of bacterial loads >10,000 CFU/G: Data from 350 wounds *30th Conference of the European Wound Management Association*. 2020. online: EWMA.
377. Cole W and Coe S. Use of a bacterial fluorescence imaging system to target wound debridement and accelerate healing: a pilot study. *J Wound Care*, 2020; 29(Sup7): S44-s52.
378. Nakagami G, Schultz G, Gibson DJ, Phillips P, Kitamura A, Minematsu T, Miyagaki T, Hayashi A, Sasaki S, Sugama J, and Sanada H. Biofilm detection by wound blotting can predict slough development in pressure ulcers: A prospective observational study. *Wound Repair Regen*, 2017; 25(1): 131-8.
379. Nakagami G, Schultz G, Kitamura A, Minematsu T, Akamata K, Suga H, Kurita M, Hayashi C, and Sanada H. Rapid detection of biofilm by wound blotting following sharp debridement of chronic pressure ulcers predicts wound healing: A preliminary study. *Int Wound J*, 2020; 17(1): 191-6.
380. Wu YF, Lee TY, Liao WT, Chuan HH, Cheng NC, and Cheng CM. Rapid detection of biofilm with modified alcian blue staining: In-vitro protocol improvement and validation with clinical cases. *Wound Repair Regen*, 2020; 28(6): 834-43.
381. Astrada A, Nakagami G, Minematsu T, Goto T, Kitamura A, Mugita Y, and Sanada H. Concurrent validity of biofilm detection by wound blotting on hard-to-heal wounds. *J Wound Care*, 2021; 30(Sup4): S4-s13.
382. Bianchera A, Buttini F, and Bettini R. Micro/nanosystems and biomaterials for controlled delivery of antimicrobial and anti-biofilm agents. *Expert Opin Ther Pat*, 2020; 30(12): 983-1000.
383. Paladini F and Pollini M. Antimicrobial silver nanoparticles for wound healing application: Progress and future trends. *Materials (Basel)*, 2019; 12(16).
384. Shepherd J. Best served small: Nano battles in the war against wound biofilm infections. *Emerg Top Life Sci*, 2020; 4(6): 567-80.
385. Yang G, Zhang M, Qi B, Zhu Z, Yao J, Yuan X, and Sun D. Nanoparticle-based strategies and approaches for the treatment of chronic wounds. *J Biomater Tissue Eng*, 2018; 8(4): 455-64.
386. Patel DR, Bhartiya SK, Kumar R, Shukla VK, and Nath G. Use of customized bacteriophages in the treatment of chronic nonhealing wounds: A prospective study. *Int J Low Extrem Wounds*, 2021; 20(1): 37-46.
387. Pinto AM, Cerqueira MA, Bañobre-López M, Pastrana LM, and Sillankorva S. Bacteriophages for chronic wound treatment: from traditional to novel delivery systems. *Viruses*, 2020; 12(2).
388. Sukumaran V and Senanayake S. Bacterial skin and soft tissue infections. *Aust Prescr*, 2016; 39(5): 159-63.
389. Esposito S, Bassetti M, Concia E, De Simone G, De Rosa FG, Grossi P, Novelli A, Menichetti F, Petrosillo N, Tinelli M, Tumbarello M, Sanguinetti M, Viale P, Venditti M, and Viscoli C. Diagnosis and management of skin and soft-tissue infections (SSTI). A literature review and consensus statement: an update. *J Chemother*, 2017; 29(4): 197-214.

390. Ayello EA, Sibbald RG, and Baranoski S, Wound Debridement, in *Wound Care Essentials: Practice Principles*, Baranoski S and Ayello EA, Editors. 2016.
391. Benbow M. Wound care: Ensuring a holistic and collaborative assessment. *Br J Community Nurs*, 2011; S6-16
392. The Royal College of Pathologists Australasia. Pathology tests. 2021. [cited October 2021]; Available from: <https://www.rcpa.edu.au/Manuals/RCPA-Manual/Pathology-Tests>.
393. WOCN. Wound Ostomy and Continenence Nurses Society. Guideline for the Prevention and Management of Pressure Ulcers. 2010. WOCN Clinical Practice Guideline Series. Mount Laurel, NJ: Wound Ostomy and Continenence Nurses Society.
394. Cohen BE, Nagler AR, and Pomeranz MK. Nonbacterial causes of lymphangitis with streaking. *J Am Board Fam Med*, 2016; 29(6): 808-12.
395. Wounds UK. 2019. Best Practice Statement: Addressing Complexities in the Management of Venous leg Ulcers. Wounds UK: London.
396. Dowsett C, Protz K, Drouard M, and Harding KG. Triangle of wound assessment made easy. *Wounds International*, 2015: 1-6.
397. Flannagan RS, Jaumouillé V, and Grinstein S. The cell biology of phagocytosis. *Annu Rev Pathol*, 2012; 7: 61-98.
398. Berlanga M and Guerrero R. Living together in biofilms: The microbial cell factory and its biotechnological implications. *Microb Cell Fact*, 2016; 15(1): 165.
399. Worksafe Queensland. Non-potable water. 2017. [cited October 2021]; Available from: <https://www.worksafe.qld.gov.au/safety-and-prevention/hazards/hazardous-exposures/non-potable-water>.
400. Nolte E, Disease Prevention, in *International Encyclopedia of Public Health*, Heggenhougen H, Editor. 2008, Academic Press: Oxford. p. 222-34.
401. Ilerano C, Manski-Nankervis J, James R, Rajkhowa A, Peel T, and Thursky K. Surgical antimicrobial prophylaxis. *Aust Prescr*, 2017; 40: 225-9.
402. Doyle JF and Schortgen F. Should we treat pyrexia? And how do we do it? *Crit Care*, 2016; 20(1): 303.
403. O'Grady NP, Barie PS, Bartlett JG, Bleck T, Carroll K, Kalil AC, Linden P, Maki DG, Nierman D, Pasculle W, and Masur H. Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America. *Crit Care Med*, 2008; 36(4): 1330-49.
404. Bhattacharjee A. Social Science Research: Principles, Methods, and Practices. 2012. [http://scholarcommons.usf.edu/oa\\_textbooks/3/](http://scholarcommons.usf.edu/oa_textbooks/3/) Global Text Project.
405. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, Colombara DV, Ikuta KS, Kissoon N, Finfer S, Fleischmann-Struzek C, Machado FR, Reinhart KK, Rowan K, Seymour CW, Watson RS, West TE, Marinho F, Hay SI, Lozano R, Lopez AD, Angus DC, Murray CJL, and Naghavi M. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. *Lancet*, 2020; 395(10219): 200-11.
406. Weinberger J, Rhee C, and Klompas M. A critical analysis of the literature on time-to-antibiotics in suspected sepsis. *J Infect Dis*, 2020; 222(Suppl 2): S110-S8.
407. Baranoski S, Ayello E, and Langemo DK, Wound Assessment, in *Wound Care Essentials: Practice Principles*, Baranoski S and Ayello E, Editors. 2016.
408. Kallstrom G. Are quantitative bacterial wound cultures useful? *J Clin Microbiol*, 2014; 52(8): 2753-6.
409. Hegarty J, Howson V, Wills T, Creedon SA, Mc Cluskey P, Lane A, Connolly A, Walshe N, Noonan B, Guidera F, Gallagher AG, and Murphy S. Acute surgical wound-dressing procedure: Description of the steps involved in the development and validation of an observational metric. *Int Wound J*, 2019; 16(3): 641-8.
410. Pollock M, Fernandes RM, Becker LA, Pieper D, and Hartling L. Chapter V: Overviews of Reviews, in *Cochrane Handbook for Systematic Reviews of Interventions version 6.2*, Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, and Welch VA, Editors. 2021, Cochrane: [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook).
411. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, Moher D, Tugwell P, Welch V, Kristjansson E, and Henry DA. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ*, 2017; 358: j4008.
412. Sterne JAC, Savović J, Page MJ, Elbers R, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, and Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ*, 2019; 366.
413. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan A-W, Churchill R, Deeks JJ, Hróbjartsson A, Kirkham J, Jüni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Schünemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, and Higgins JP. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ*, 2016; 355: i4919.
414. Fitch K, Bernstein SJ, Aguilar MD, Burnand B, LaCalle JR, Lázaro P, van der Loo M, McDonnell J, Vader JP, and Kahan JP. The RAND/UCLA Appropriateness Method User's Manual. 2001. Santa Monica, CA: RAND.